Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose critical information about the Novum LVP, including systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares during the class period (February 23, 2022, to July 30, 2025) and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Points - A class action lawsuit has been filed against KBR, Inc. for allegedly making false and misleading statements regarding its partnership with the U.S. Department of Defense's Transportation Command [7] - The lawsuit covers investors who purchased KBR securities between May 6, 2025, and June 19, 2025, and they have until November 18, 2025, to apply as lead plaintiffs [7] Allegation Details - The complaint alleges that KBR was aware of concerns from TRANSCOM about HomeSafe's ability to fulfill its Global Household Goods Contract but failed to disclose this information [3] - KBR allegedly misled investors by claiming that its partnership with TRANSCOM would continue to grow despite these concerns [3] - The company's public statements during the class period are claimed to be false and materially misleading, leading to investor damages when the truth was revealed [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions can contact the law firm Bragar Eagel & Squire, P.C. for assistance [4] - There is no cost or obligation for investors to reach out for more information [4]

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, exposing patients to serious injury or death [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares during the class period (February 23, 2022, to July 30, 2025) and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified class period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements while concealing material adverse facts about the company's advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with their ad platform and other factors [8]. Stock Price Impact - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8].

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial outlook during the class period from February 27, 2025, to August 11, 2025 [6]. Allegation Details - The lawsuit claims that PubMatic failed to disclose significant adverse facts, including a major demand-side platform (DSP) buyer shifting clients to a new platform, resulting in reduced ad spend and revenue for PubMatic [6]. - The complaint highlights that the positive statements made by the company regarding its business were misleading and lacked a reasonable basis due to these undisclosed issues [6]. Financial Impact - Following the release of its second quarter 2025 financial report on August 11, 2025, which revealed a reduction in ad spend from a top DSP partner, PubMatic's stock price dropped by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Dow, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial condition during the Class Period from January 30, 2025, to July 23, 2025 [1][7]. Allegation Details - Defendants overstated Dow's ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - The negative impacts of competitive pressures, softening global sales, and product oversupply on Dow's business were understated [3]. - Public statements made by the Defendants were materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Dow shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina, and specializes in commercial and securities litigation [5].

Core Points - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position [7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, statements made by the defendants about the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements while concealing material adverse facts about the company's advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with their ad platform and other factors [8]. Stock Performance - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8]. Legal Actions - Investors who purchased Snap securities between April 29, 2025, and August 5, 2025, are encouraged to contact the law firm Bragar Eagel & Squire to discuss their legal rights and options [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 20, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the Class Period from August 8, 2024, to August 14, 2025 [3][8]. Allegation Details - The lawsuit claims that Nutex engaged in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate material weaknesses in its internal controls over financial reporting [3]. - The company reportedly misclassified stock-based compensation obligations, increasing the risk of failing to file timely financial reports with the SEC [3]. - Overall, the public statements made by Nutex were deemed materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Nutex shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [8] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [8] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price drop of nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4] - The law firm offers no cost or obligation for consultations regarding the lawsuit [4]